Simpson Thacher represented JPMorgan Chase Bank, N.A. as administrative agent and lead left arranger in connection with Neurocrine Biosciences Inc.’s (“Neurocrine”) entry into a new $1 billion five-year senior secured revolving credit facility (the “Revolving Credit Facility”). The proceeds of borrowings under the Revolving Credit Facility will be used for general corporate purposes, including permitted investments and acquisitions.
Neurocrine is a leading biopharmaceutical company dedicated to discovering, developing and commercializing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Neurocrine has a portfolio of U.S. Food & Drug Administration approved products for the treatment of tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis and uterine fibroids, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across its core therapeutic areas.
The Simpson Thacher team includes Jessica Tuchinsky, Sophie Skinner and Claire Kamau (Banking and Credit); Vanessa Burrows and Jacob Madden (Healthcare); Timothy Gallagher (Real Estate); Matthew Hart (Capital Markets); Nathan Utterback (Derivatives); Michael Mann (Tax); George Gerstein (ERISA); Toby Chun and Deepa Sarkar (Environmental); and Seth Davis (Registered Funds).